Evotec SE announced today that the Company reached additional programme designations within its neuroscience collaboration with Bristol Myers Squibb triggering payments of in total US$ 40 m to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reaches-programme-designations-in-neuroscience-collaboration-with-bristol-myers-squibb-6118